Drug intelligence / Profile preview

bi 3802876

Development stage: Phase 2
Lead developer: Boehringer Ingelheim
Modality: Small Molecules
Administration: Intravenous

Overview

BI 3802876 is an investigational drug developed by Boehringer Ingelheim. It is currently in Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers. The mechanism of action and therapeutic area are not publicly disclosed[2][4][5]. The primary objective of ongoing studies is to evaluate the frequency of drug-related adverse events compared to placebo, as well as to describe pharmacokinetic parameters[1][3][5].

Beyond the preview

Go deeper on bi 3802876.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bi 3802876.

Explore the full profile